Belite Bio Stock (NASDAQ:BLTE)
Previous Close
$82.76
52W Range
$31.00 - $86.53
50D Avg
$59.90
200D Avg
$49.02
Market Cap
$2.54B
Avg Vol (3M)
$57.75K
Beta
-1.60
Div Yield
-
BLTE Company Profile
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
BLTE Performance
Peer Comparison
| Ticker | Company |
|---|---|
| ANAB | AnaptysBio, Inc. |
| VIGL | Vigil Neuroscience, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| CNTA | Centessa Pharmaceuticals plc |
| IKNA | Ikena Oncology, Inc. |
| LRMR | Larimar Therapeutics, Inc. |
| ALGS | Aligos Therapeutics, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| GLTO | Galecto, Inc. |
| TRDA | Entrada Therapeutics, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| IMRX | Immuneering Corporation |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| MOLN | Molecular Partners AG |
| CELC | Celcuity Inc. |
| AADI | Aadi Bioscience, Inc. |